GRP78 elevation in tumor cells has been shown to confer resistance to chemotherapeutic drugs, including cisplatin, 5-FU, paclitaxel, docetaxel, sorafenib, bortezomib, etoposide, doxorubicin, temozolomide, vinblastine and camptothecins, as well as anti-hormonal, anti-angiogenesis, chromatin-modifying agents and radiation therapy [1, 14–17]. Here, HSPA5 is linked to neoplasm.